Search results
Results from the WOW.Com Content Network
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...
Parents may also consider a drug treatment for attention deficit as avoidable. Alternative treatments to a stimulant medication range from natural products to psychotherapeutic techniques and highly technological interventions. It has been argued that although texts that promote alternative therapies do not directly accuse parents of inadequacy ...
This is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (ADHD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in ...
The treatment of Attention Deficit Hyperactivity Disorder (ADHD) commonly involves a multimodal approach, combining various strategies to address the complex nature of the disorder. This comprehensive approach includes psychological, behavioral, pharmaceutical, and educational interventions tailored to the individual's specific needs.
Parent management training (PMT), also known as behavioral parent training (BPT) or simply parent training, is a family of treatment programs that aims to change parenting behaviors, teaching parents positive reinforcement methods for improving pre-school and school-age children's behavior problems (such as aggression, hyperactivity, temper tantrums, and difficulty following directions).
In 2010, guanfacine was approved by the FDA for the treatment of attention deficit hyperactivity disorder for people 6 to 17 years old. [16] It was approved for ADHD by the European Medicines Agency under the name Intuniv in 2015. [61] It was added to the Australian Pharmaceutical Benefits Scheme for the treatment of ADHD in 2018. [62]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Atomoxetine is sometimes used in the treatment of cognitive impairment and frontal lobe symptoms due to conditions like traumatic brain injury (TBI). [44] [45] It is used to treat ADHD-like symptoms such as sustained attentional problems, disinhibition, [46] lack of arousal, fatigue, and depression, including symptoms from cognitive disengagement syndrome. [44]